Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) Short Interest Down 40.3% in August

Cyclacel Pharmaceuticals, Inc. (NASDAQ:BGMS) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totaling 34,897 shares, a drop of 40.3% from the August 15th total of 58,435 shares. Currently, 0.8% of the shares of the stock are sold short. Based on an average daily volume of 13,850 shares, the days-to-cover ratio is currently 2.5 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Cyclacel Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Cyclacel Pharmaceuticals presently has a consensus rating of “Sell”.

Cyclacel Pharmaceuticals Stock Up 5.1%

Shares of NASDAQ:BGMS opened at $0.92 on Friday. Cyclacel Pharmaceuticals has a 52 week low of $0.57 and a 52 week high of $6.70. The stock has a market cap of $5.09 million, a PE ratio of -0.25 and a beta of -0.40. The company’s fifty day moving average is $0.91 and its 200 day moving average is $0.94.

Cyclacel Pharmaceuticals (NASDAQ:BGMS) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.08) EPS for the quarter. Cyclacel Pharmaceuticals had a negative net margin of 118.27% and a negative return on equity of 31.60%. The firm had revenue of $0.34 million for the quarter.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies that target the cell cycle and related regulatory pathways for the treatment of cancer and other proliferative diseases. The company’s research and development efforts center on kinase and cell-cycle inhibitors designed to disrupt tumor growth and induce cancer cell death. Cyclacel advances programs through preclinical development and clinical trials with the aim of delivering new therapeutic options for patients with solid tumors and hematologic malignancies.

Key activities at Cyclacel include in-house drug discovery, translational research, and the clinical development of lead candidate molecules.